Mosanna Therapeutics AG closed its USD 80m Series-A-funding round.

The clinical-stage biotech company headquartered in Basel, Switzerland, is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea (OSA) that aims to restore the body’s natural airway control. The financing was led by EQT Life Sciences and Pivotal bioVenture Partners, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as Supermoon Capital and High-Tech Gründerfonds (HTGF).

VISCHER advised Mosanna Therapeutics AG in this financing. The VISCHER team is led by Matthias Staehelin (Partner, Corporate/M&A) and includes Nadia Tarolli (Partner, Tax), Luzius Zumstein (Managing Associate, Corporate/M&A), Diego Anzante (Associate, Tax) and Timothy Woodtli (Senior Associate, Corporate/M&A) .

Author: Luzius Zumstein